Continuous 2 is an active project aiming to address the growing demand for cost-effective biologics treatments. With the global biopharmaceutical market estimated to grow to 3.9bn by 2024, the industry must act quickly to make these life-changing drugs more accessible to patients, and respond to the demand for flexible manufacturing technology that delivers real-time release of biotherapeutics.
UK Continuous 2 is building on the achievements of two previous projects:
The July edition of our People Pathways newsletter is now available to read here.
You can read about:
✴ New and upcoming One Nucleus courses
✴ Registration open for the next BLSA SIG webinar
✴ Reflections and takeaways from our Neurodiversity webinar
✴ New mentoring opportunities
and more...
French biophysics pioneer Depixus has launched its inaugural Research Program, offering free access to the company’s unique single molecule interactomics technology.
Depixus’ scalable magnetic force spectroscopy (MFS) platform is the first technology that allows researchers to simultaneously explore dynamic interactions between thousands of individual molecules in near real-time.
Boston MA and London UK, 31 July 2024 - One Nucleus and Life Science Nation (LSN) are pleased to announce the co-location of their renowned Genesis 2024 and Redefining Early Stage Investments (RESI) conferences, scheduled to take place on 4 December 2024, in London. The Genesis Conference programme will be at 1 Wimpole Street, and RESI will be at 11 Cavendish Square, allowing attendees to participate in either or both events just a few steps away from each other.
Metrion Biosciences' webinar ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ enabled attendees to learn how an hiPSC-CM model can help provide clear decision-making data for their project team, avoiding costly issues related to QTc and QRS cardiac liabilities in the clinic.
Presentations were received from:
Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.
Q2 2024 Take-Up Statistics
• Golden Triangle leasing activity totalled 39,700 sq ft in Q2 2024.
• This lull is typical for the second quarter, with 2024 likely to be the fourth year out of the past six where Q2 has reported the lowest quarterly volume of the year.
Cambridge, UK, 23 July 2024: Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities.
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets
Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer
Appointment of experienced pre-clinical CRO specialist to support accelerated expansion into key global markets